https://www.live-feeds.com/feed/a-transformative-narcolepsy-drug-opens-new-opportunities-in-neuroscienceContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/a-transformative-narcolepsy-drug-opens-new-opportunities-in-neurosciencehttps://www.live-feeds.com/feed/a-transformative-narcolepsy-drug-opens-new-opportunities-in-neuroscience#u64736Fri, 11 Sep 2026 05:23:12 +0000The FDA has approved oveporexton, a first-in-class orexin agonist designed to treat Narcolepsy Type 1. Takeda has published Phase 3 study data supporting the drug's efficacy in reducing excessive daytime sleepiness. The medication has secured global approvals and is described as a transformative development in neuroscience. By targeting the orexin system, the drug aims to lift the fog of sleepiness for patients who previously had limited treatment options.Why it mattersNarcolepsy Type 1 is characterized by a deficiency in orexin, a neurotransmitter that regulates wakefulness. Previous tre